Videos uploaded by user “AJMCtv”
Atopic Dermatitis: Dupilumab and Increase in Patient Quality of Life
Patient, Elizabeth Acuna, describes some of the medications she has been on, and currently is taking, to treat her atopic dermatitis, and their effect on her quality of life.
Views: 3495 AJMCtv
Surya Singh, MD, Explains the Buy-and-Bill Model
Surya Singh, MD, Vice President, Medical Benefit Management, CVS Caremark, says the buy-and-bill model is most typically applied to the provider space, and more specifically to physicians' offices. It describes the supply chain for infusion medications, predominately self-injectables that require clinical monitoring, and that are administered or sourced through practitioners. In this model, buying refers to the procurement of the drugs by the practice, and the billing refers to the bill sent directly to payers. "There's been a growth in the number of hospital outpatient centers that source drugs and then bill payers directly through their contracts," says Dr Singh; "And that's on the rise given the acquisitions of physician practices in oncology and in other relevant specialties."
Views: 1957 AJMCtv
SGLT2 Inhibition and CVD Outcomes in Type 2 Diabetes
In this segment, Zachary Bloomgarden, MD; Robert Gabbay, MD, PhD, FACP; Silvio Inzucchi, MD; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, discuss sodium-glucose co-transporter 2 inhibition in patients with diabetes and corresponding outcomes on cardiovascular events.
Views: 1425 AJMCtv
Dr Steven Nissen Argues for Aggressively Lowering LDL Cholesterol
There is an ongoing debate about how aggressively to lower low-density lipoprotein (LDL) cholesterol, but Steve Nissen, MD, of Cleveland Clinic, argues that studies have shown an aggressive approach to lowering LDL always shows benefits.
Views: 1575 AJMCtv
Introduction: Value-Based Purchasing in Healthcare Reform
During the opening segment of this program, part of the Healthcare Reform Stakeholders Summit, Spring 2015 series, moderator Dennis Patrick Scanlon, PhD, asks managed care stakeholders Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, for their insights on the goals of value-based purchasing programs and the roles of various stakeholders in these programs.
Views: 2276 AJMCtv
Nat Turner on the Main Barriers for Flatiron Health in Providing Care in Oncology
Nat Turner, co-founder and CEO of Flatiron Health, says that clinical research accessibility is one of the biggest barriers in oncology care that Flatiron Health is working to remove.
Views: 685 AJMCtv
Practical Implications of the CANVAS Trial
Expert John Anderson, MD, reviews data from the CANVAS trial with canagliflozin and offers his perspective on the practical implications of the recent findings.
Views: 522 AJMCtv
Today's HIV Treatment Challenges
Peter L. Salgo, MD; Elly Fatehi, PharmD, MPH; Michael Sension, MD; and Jeffrey Dunn, PharmD, offer their perspectives on the current treatment challenges in human immunodeficiency virus, including medication adherence.
Views: 880 AJMCtv
Dr Manisha Madhoo Highlights the Benefits of Mydayis for Adult ADHD
The new ADHD drug for adults, Mydayis, works with multiple beads being released at different times of the day so patients are only taking one medication that lasts for up to 16 hours instead of multiple dosings throughout the day, explained Manisha Madhoo, MD, vice president of Global Medical Affairs, Neuroscience, Shire.
Views: 2681 AJMCtv
GLP-1 Receptor Agonists and Cardiovascular Benefit
Expert John Anderson, MD, reviews the cardiovascular outcomes data available to date with GLP-1 receptor agonists in type 2 diabetes.
Views: 477 AJMCtv
Accountable Care Organizations and Risk
The accountable care organization (ACO) programs—the Pioneer, Shared Savings, and Next Generation models—and how they relate to provider risk is addressed by panel members Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, during this 12th session of the Healthcare Reform Stakeholder Summit. Risk factors for various models are also discussed.
Views: 1889 AJMCtv
Understanding Cardiovascular Benefit With the LEADER Trial
John B. Buse, MD, PhD, offers his perspective on the LEADER trial with liraglutide and the potential reasons for the cardiovascular effects in patients with type 2 diabetes.
Views: 535 AJMCtv
Limitations of ICER’s Value Assessment Framework Tool
Alan Balch, PhD, discusses the Institute for Clinical and Economic Review’s (ICER’s) Value Assessment Framework tool that aims to provide stakeholders in healthcare with evidence to make more informed decisions regarding new cancer therapies. Dr Balch also considers limitations to the tool’s effectiveness.
Views: 571 AJMCtv
HIV Guideline Update
Peter L. Salgo, MD; Michael Sension, MD; Jeffrey Dunn, PharmD; and Elly Fatehi, PharmD, MPH, review the updates to the Department of Health and Human Services treatment guideline for most people with human immunodeficiency virus.
Views: 612 AJMCtv
Multiple Myeloma: Frontline Daratumumab Combinations
Amrita Krishnan, MD, FACP, elucidates various combination treatment approaches making use of daratumumab in the frontline setting for patients with newly diagnosed multiple myeloma.
Views: 342 AJMCtv
Dr. Richard Channick Addresses a New Treatment in Pulmonary Arterial Hypertension
In this video, Richard Channick, MD, Director, Pulmonary Hypertension and Thromboendarterectomy Program, Massachusetts General Hospital, Boston, MA, speaks about the use of Macitentan for the treatment of pulmonary arterial hypertension (PAH). Dr Channick says that Macitentan, compared to placebo, significantly improved morbidity in PAH. The results demonstrated in the SERAPHIN clinical trial also proved that Macitentan decreased hospitalizations in patients with PAH. This video was taken on May 20, 2013, at the ATS 2013 International Conference in Philadelphia, PA.
Views: 1821 AJMCtv
Rick Doubleday Outlines the Partnership Between Dexcom and Fitbit
Rick Doubleday, the executive vice president and chief commercial officer at Dexcom, discusses his company's new partnership with Fitbit and what patients with both type 1 and type 2 diabetes will get out of it.
Views: 647 AJMCtv
Dr Emma Guttman-Yassky on Current and Future Atopic Dermatitis Treatments
In the search for a safe and effective treatment for atopic dermatitis (AD), new research looks at the immune pathway of psoriasis to potentially help target AD, according to Emma Guttman-Yassky, MD, PhD, of the Icahn School of Medicine at Mount Sinai Medical Center in New York.
Views: 1052 AJMCtv
Analysis of the Oncology Care Model
Bruce Feinberg, DO; Scott Gottlieb, MD; and Ted Okon, MBA, discuss the recent establishment of the Oncology Care Model by the CMS and compare its structure with the Community Oncology Alliance’s Oncology Medical Home model.
Views: 967 AJMCtv
Comparison of Guidelines From ADA and AACE
Zachary T. Bloomgarden, MD, MACE, describes the treatment options available for the management of diabetes and remarks on the differences between the clinical guidelines that have been released to assist healthcare providers in managing patients with diabetes.
Views: 1386 AJMCtv
Dr Tina Joseph Discusses Collaborative Practice Agreements Between Pharmacists, Physicians
Tina Joseph, PharmD, BCACP, assistant professor, college of pharmacy, Nova Southeastern University, discusses collaborative practice agreements between pharmacists and physicians as well as the challenges with and best practices for successful implementation.
Views: 345 AJMCtv
Dr Liz Zhou Explains Basal Insulin Switching Study on Toujeo
Liz Zhou, MD, director of evidence-based medicine at Sanofi Medical Affairs outlined the purpose of a study on real-world results of comparing basal insulin dose changes in type 2 diabetes patients using Lantus who either stay on Lantus or switch to Toujeo.
Views: 524 AJMCtv
The Evolution of Buy-and-Bill
Michael Kolodziej, MD, and Brian Kiss, MD, discuss the origins of the buy-and-bill model and describe changes needed in the model based on the evolution of healthcare reimbursement strategies in the United States.
Views: 977 AJMCtv
Patient Selection for Treatment With Ibrutinib in CLL
Steven Coutre, MD, highlights the latest drug approval of ibrutinib for frontline therapy in patients with chronic lymphocytic leukemia and its role in long-term treatment.
Views: 1387 AJMCtv
John B. Buse, MD, PhD, discusses the efficacy and safety findings from the EMPA-REG OUTCOME trial with empagliflozin in patients with type 2 diabetes mellitus.
Views: 340 AJMCtv
Innovative Healthcare Delivery Models
New delivery models related to the recent healthcare reform legislation may help drive up utilization, as discussed by Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, in this seventh segment of the Healthcare Reform Stakeholders Summit, Spring 2015 series. They theorize that healthcare convenience and availability may actually lead to a loss in coordination of care.
Views: 973 AJMCtv
Initiating Frontline Therapy in CLL
Susan M. O’Brien, MD, describes the guideline recommendations for initiating therapy in patients with chronic lymphocytic leukemia, the available frontline therapy options, and patient selection for some of the options.
Views: 224 AJMCtv
The Biology and Diagnosis of CLL
Susan M. O’Brien, MD, discusses the underlying biology of chronic lymphocytic leukemia and factors to consider for diagnosis, such as mutational status and chromosomal aberrations.
Views: 223 AJMCtv
Panel Discussion: Addressing the Needs of Patients, Part 1
Panel discussion moderated by Clifford Goodman, PhD, of The Lewin Group. Panelists were Andrea Baer, MS, of Mended Hearts, Inc; Jalpa A. Doshi, PhD, of University of Pennsylvania; Mary Richards of Partners for Better Care; Veena Shankaran, MD, MS, of University of Washington and Fred Hutchinson Cancer Research Center; and Kai Yeung, PharmD, PhD, of Group Health Research Institute. The discussion took place at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medication, which was co-hosted by the PAN Foundation and The American Journal of Managed Care.
Views: 3339 AJMCtv
Lidia Fonseca on the Evolution of On-Demand Data in the Healthcare System
The use of on-demand data in the healthcare setting has gone through an evolution, where the beginning steps were about pulling information into 1 pool and then understanding how to analyze it. According to Lidia Fonseca, senior vice president and chief information officer of Quest Diagnostics, the next step in this process is integrating this technology into the workflow of physicians and using the information in a real time and impactful way.
Views: 578 AJMCtv
Measuring the Success of Clinical Pathways
Following their discussion on the implementation of clinical pathways programs in medical oncology, the panelists consider variables that are important to consider when collecting data to measure the success of a pathways program.
Views: 289 AJMCtv
Episode 10 - Treating Mild and Severe Hemophilia
During this segment, Patrick F. Fogarty, MD, discusses the treatment goals for hemophilia, based on disease severity. Dr Fogarty defines prophylaxis, explains primary and secondary prophylaxis for the treatment of mild and severe hemophilia, and discusses the recommended target trough levels and dosage requirements based on disease severity. He continues by discussing how treatment expectations are similar between patients, their family members, and providers. From a pediatric standpoint, Dr Fogarty stresses the importance of providing patients the best opportunity for a normal lifestyle, and explains that as longer-acting proteins continue to develop, there is an opportunity to administer intravenous therapy less frequently. Dr Fogarty concludes by briefly discussing the benefits of the agents that are currently available to treat patients with mild and severe hemophilia, and cites a recent study that treated patients with a regimen of recombinant clotting factor 8 concentrate and revealed positive results on patients' quality of life.
Views: 298 AJMCtv
CLL: Rationale for Ibrutinib and Sequencing
Susan M. O’Brien, MD, reviews the clinical data supporting the use of ibrutinib as up-front therapy for patients with chronic lymphocytic leukemia and the factors to consider when sequencing therapies.
Views: 186 AJMCtv
Is the Oncology Care Model Patient Centered?
Rena M. Conti, PhD; Brenton Fargnoli, MD; and Andrew L. Pecora, MD, CPE, describe the objectives of the Oncology Care Model (OCM) and the requirements for OCM program eligibility.
Views: 305 AJMCtv
Episode 4 - The Link Between Diabetes and Cardiovascular Disease
Diabetes is an insidious cardiometabolic condition that continues to affect a growing population of young Americans, and is associated with high blood pressure, lipid abnormalities, and renal disease. The disease and its clinical sequelae are tightly interwoven with cardiovascular disease (CVD), acute coronary syndrome, and stroke. Consequently, there are substantial clinical implications for the optimal management of any underlying cardiometabolic disorder. While the topic of "metabolic syndrome" remains controversial and inconsistently defined, Dr Michael Weber emphasizes that glycosylated hemoglobin A1c (HbA1c), while the standard measure for the management of diabetes, is only one component of the overall picture - it is also essential to appropriately control body weight and size, blood pressure, and lipid levels.
Views: 117 AJMCtv
Dr Farzad Mostashari on Integrating Technology, Strategy, and Analytics
Farzad Mostashari, MD, co-founder and CEO of Aledade and former National Coordinator of Health Information Technology, discusses the benefits of Aledade’s technology, combined with its strategies and analytics, and how these tools are implemented among the practices with which Aledade is working.
Views: 375 AJMCtv
Results From the CANVAS Trial
John B. Buse, MD, PhD, reviews the efficacy and safety findings from the CANVAS study of canagliflozin in patients with type 2 diabetes mellitus.
Views: 1347 AJMCtv
The CHAARTED Study—Treatment of CRPC with Docetaxel
In this segment, Christopher Sweeney, MBBS, discusses the results of the ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED). Dr Sweeney also discusses how the results of CHAARTED have impacted the treatment of patients with prostate cancer and influenced research on combination therapy.
Views: 335 AJMCtv
Impact of the EMPA-REG Study in Type 2 Diabetes
In the opening segment of this AJMC Peer ExchangeTM, moderator Dennis P. Scanlon, PhD, discusses results of the EMPA-REG OUTCOME trial that demonstrated treatment effectiveness in both diabetes and cardiovascular mortality.
Views: 520 AJMCtv
Wet AMD: Understanding the Role of Anti-VEGF Therapy
Panelists Peter L. Salgo, MD; Charles Wykoff, MD, PhD; and Jared Nielsen, MD, describe the mechanism of action and role of anti-VEGF therapies in the treatment of wet age-related macular degeneration.
Views: 312 AJMCtv
GLP-1 Receptor Agonists: Initial Cardiovascular Evidence
John B. Buse, MD, PhD, reviews the findings from the ELIXA trial with lixisenatide in patients with type 2 diabetes.
Views: 319 AJMCtv
Importance of Data Sharing in Healthcare
Despite the potential benefits of sharing healthcare data, Rena M. Conti, PhD; Brenton Fargnoli, MD; and Andrew L. Pecora, MD, CPE; note that there are also several associated challenges. The panelists suggest that engaging patients to be responsible for their electronic health records can improve care.
Views: 337 AJMCtv
Dr John Eikelboom: COMPASS' Rivaroxaban Plus Aspirin Will Become Standard for CAD, PAD
The rivaroxaban plus aspirin combination therapy to treat patients with stable coronary or peripheral artery disease showed such benefits in the COMPASS trial that it should become the standard of care, said John Eikelboom, MBBS, MSc, FRCPC, associate professor at McMaster University.
Views: 368 AJMCtv
Why EMPA-REG Results Make This a “Very Exciting Time” in Diabetes Care
Dennis P. Scanlon, PhD; Zachary T. Bloomgarden, MD, MACE; Robert Gabbay, MD, PhD, FACP; Michael Gardner, MD; and John A. Johnson, MD, MBA; discuss the results of recent clinical trials that evaluated cardiovascular outcomes associated with various diabetes treatments when used as add-on therapy.
Views: 2216 AJMCtv
Cardiovascular Benefit With SGLT2 Inhibition
John B. Buse, MD, PhD, discusses the potential reasons for the cardiovascular risk reduction benefits associated with SGLT2 inhibition in patients with type 2 diabetes mellitus.
Views: 208 AJMCtv
Pathophysiology and Diagnosis of Multiple Myeloma
Jatin Shah, MD, explains that there is no clear reason for why patients develop multiple myeloma, and so there's no clear risk factor.
Views: 455 AJMCtv
Pathophysiology, Prognostic Factors, and Potential Risks that Influence Treatment in CLL
Steven Coutre, MD, discusses the various factors that influence treatment decisions in chronic lymphocytic leukemia and the potential for more individualized approaches.
Views: 478 AJMCtv
NRAS Mutations in Melanoma
Richard W. Joseph, MD, highlights clinical trial results showing that melanoma patients with NRAS mutations tend to have better response rates to immunotherapy compared with patients with wild-type NRAS.
Views: 218 AJMCtv
Dr. Tobias Loddenkemper, MD discusses challenges and goals with treatment of RSE
Dr. Tobias Loddenkemper, MD, the Assistant Professor in Neurology at Harvard Medical School, discusses the challenges and goals associated with the treatment of refractory status epilepticus (SE) in the pediatric populations, especially noting the cognitive and developmental considerations. This video was taken on Friday, November 30th at the American Epilepsy Society's 2012 Annual Meeting in San Diego, CA.
Views: 802 AJMCtv